AICLRs 31.0+9.1%BERGRs 36.5-14.4%PRLRs 147.7+44.2%AGLRs 16.9+69.1%KAPCORs 51.5+57.5%SITCRs 52.5-4.6%NMLRs 374.1+210.3%NETSOLRs 5,771.3+29.7%BOPRs 138.7-11.7%PSORs 443.1+105.3%NPLRs 18.7+89.3%FMLRs 288.6+94.9%MARIRs 23.5-11.0%THALLRs 140.6+110.3%NRLRs 61.3-22.3%HBLRs 451.9-6.7%SYSRs 1,566.1+36.2%GATMRs 79.9+33.4%GHGLRs 1,075.6+1.5%FCEPLRs 85.0+61.6%PNSCRs 566.1-42.5%AVNRs 463.8+57.3%FFLRs 135.5+33.3%AGTLRs 159.5-34.9%FEROZRs 274.0+45.3%SRVIRs 38.0+63.0%ILPRs 26.7+20.5%KELRs 71.8+64.8%MLCFRs 1.8-5.9%HTLRs 157.8+46.7%PIOCRs 54.6+58.7%IGIHLRs 98.5-4.8%EFERTRs 76.5+20.3%FFCRs 14.2-30.0%GHNIRs 476.1+34.4%PTCRs 14,713.1+1.5%TPLPRs 2,078.1+10.1%UBLRs 355.3-25.8%ISLRs 171.0+2.7%APLRs 38.3+9.0%ABOTRs 4.4-26.4%PKGSRs 61.2+35.3%FABLRs 263.0-1.9%ATLHRs 10.6-5.5%OGDCRs 71.0+43.4%MTLRs 106.9-27.7%NCLRs 5.7+56.9%UNITYRs 758.2+41.8%LUCKRs 67.7+22.9%KTMLRs 158.5+51.2%SNBLRs 172.8+16.1%BWCLRs 196.5+40.1%CHCCRs 25.0-4.0%ASTLRs 9.1+14.5%ITTEFAQRs 12.3-9.9%AGPRs 30.8-42.3%HINOONRs 61.3-35.9%ENGRORs 68.6+46.4%ATRLRs 26.4+81.9%SHELRs 187.1-5.4%JDWSRs 2.1+20.6%EFUGRs 50.9+44.1%KOHCRs 79.1+42.0%BNWMRs 54.3+62.8%GLAXORs 56.9+14.0%CNERGYRs 49.2-1.8%JSBLRs 377.8-24.1%SEARLRs 21.7-21.2%MCBRs 81.8-4.4%BAFLRs 110.1+14.1%TGLRs 236.2-8.1%NCPLRs 27.7+19.9%AIRLINKRs 81.3+23.7%PAELRs 27.5+77.4%PAKTRs 1.7+3.6%INDURs 74.3-34.6%EPCLRs 17.8-50.1%TRGRs 100.9+18.5%SNGPRs 3.6-7.2%MEBLRs 95.1+11.0%PPLRs 12.0+27.2%POLRs 149.8+69.1%BAHLRs 123.3-17.6%GWLCRs 18.0+9.8%ACPLRs 41.8+19.4%FCCLRs 146.4+6.4%HCARRs 752.9-10.6%NBPRs 173.6-16.9%FATIMARs 237.9+68.5%SSGCRs 12.9+40.7%AKBLRs 268.1-10.1%LOTCHEMRs 65.9-7.3%NATFRs 5.0-57.8%MUGHALRs 76.8-47.2%PSMCRs 514.2-32.5%ICIRs 268.1+5.8%HUBCRs 48.3+16.8%NESTLERs 4.6-50.6%ARPLRs 89.9-12.9%DGKCRs 681.9+39.9%PSELRs 113.5-0.4%AICLRs 31.0+9.1%BERGRs 36.5-14.4%PRLRs 147.7+44.2%AGLRs 16.9+69.1%KAPCORs 51.5+57.5%SITCRs 52.5-4.6%NMLRs 374.1+210.3%NETSOLRs 5,771.3+29.7%BOPRs 138.7-11.7%PSORs 443.1+105.3%NPLRs 18.7+89.3%FMLRs 288.6+94.9%MARIRs 23.5-11.0%THALLRs 140.6+110.3%NRLRs 61.3-22.3%HBLRs 451.9-6.7%SYSRs 1,566.1+36.2%GATMRs 79.9+33.4%GHGLRs 1,075.6+1.5%FCEPLRs 85.0+61.6%PNSCRs 566.1-42.5%AVNRs 463.8+57.3%FFLRs 135.5+33.3%AGTLRs 159.5-34.9%FEROZRs 274.0+45.3%SRVIRs 38.0+63.0%ILPRs 26.7+20.5%KELRs 71.8+64.8%MLCFRs 1.8-5.9%HTLRs 157.8+46.7%PIOCRs 54.6+58.7%IGIHLRs 98.5-4.8%EFERTRs 76.5+20.3%FFCRs 14.2-30.0%GHNIRs 476.1+34.4%PTCRs 14,713.1+1.5%TPLPRs 2,078.1+10.1%UBLRs 355.3-25.8%ISLRs 171.0+2.7%APLRs 38.3+9.0%ABOTRs 4.4-26.4%PKGSRs 61.2+35.3%FABLRs 263.0-1.9%ATLHRs 10.6-5.5%OGDCRs 71.0+43.4%MTLRs 106.9-27.7%NCLRs 5.7+56.9%UNITYRs 758.2+41.8%LUCKRs 67.7+22.9%KTMLRs 158.5+51.2%SNBLRs 172.8+16.1%BWCLRs 196.5+40.1%CHCCRs 25.0-4.0%ASTLRs 9.1+14.5%ITTEFAQRs 12.3-9.9%AGPRs 30.8-42.3%HINOONRs 61.3-35.9%ENGRORs 68.6+46.4%ATRLRs 26.4+81.9%SHELRs 187.1-5.4%JDWSRs 2.1+20.6%EFUGRs 50.9+44.1%KOHCRs 79.1+42.0%BNWMRs 54.3+62.8%GLAXORs 56.9+14.0%CNERGYRs 49.2-1.8%JSBLRs 377.8-24.1%SEARLRs 21.7-21.2%MCBRs 81.8-4.4%BAFLRs 110.1+14.1%TGLRs 236.2-8.1%NCPLRs 27.7+19.9%AIRLINKRs 81.3+23.7%PAELRs 27.5+77.4%PAKTRs 1.7+3.6%INDURs 74.3-34.6%EPCLRs 17.8-50.1%TRGRs 100.9+18.5%SNGPRs 3.6-7.2%MEBLRs 95.1+11.0%PPLRs 12.0+27.2%POLRs 149.8+69.1%BAHLRs 123.3-17.6%GWLCRs 18.0+9.8%ACPLRs 41.8+19.4%FCCLRs 146.4+6.4%HCARRs 752.9-10.6%NBPRs 173.6-16.9%FATIMARs 237.9+68.5%SSGCRs 12.9+40.7%AKBLRs 268.1-10.1%LOTCHEMRs 65.9-7.3%NATFRs 5.0-57.8%MUGHALRs 76.8-47.2%PSMCRs 514.2-32.5%ICIRs 268.1+5.8%HUBCRs 48.3+16.8%NESTLERs 4.6-50.6%ARPLRs 89.9-12.9%DGKCRs 681.9+39.9%PSELRs 113.5-0.4%

Compare Watch

HINOON

HOLD

Highnoon Laboratories

Pharmaceuticals · 0.36% of the KSE-100

Price

Rs 61.33

Market cap

Rs 12.7bn

12-month return

-35.9%

Rank

57 of 101

50composite

Rule-based57

ML ranker36

Conviction59

Why the engine ranks it here

Highnoon Laboratories (HINOON) screens as fairly valued against the rest of the KSE-100, ranking 57 of 101 on a composite score of 50/100.

Highnoon Laboratories sits in the Pharmaceuticals sector and scores best on balance-sheet strength (66/100), weakest on price trend (36/100). At PKR 61.33 the shares trade on a P/E of 0.5x, 0.13x book, a 56.4% dividend yield. The Piotroski F-Score is 8 of 9 (very strong) and the Altman Z''-Score is 8.32 (financially sound).

What it does well

HINOON covers its finance cost 10.3x over.

Balance-sheet strength

HINOON carries modest debt at 0.27x of equity.

Balance-sheet strength

HINOON grew earnings 79.8% year on year.

Growth

What holds it back

HINOON has fallen -36.1% over the last year excluding the latest month.

Price trend

HINOON trades -21.7% relative to its 200-day average.

Price trend

HINOON has lagged the KSE-100 by -28.0% over six months.

Price trend

What would change this view

→ the price reclaiming its 200-day average on rising volume

Five-pillar breakdown

Each pillar scores the company against sector peers, where 50 is the sector average.

Profitability & earnings quality30% weight60

Valuation25% weight55

Balance-sheet strength20% weight66

Growth15% weight58

Price trend10% weight36

The classic screens

Piotroski tests nine accounting facts about improvement; Altman scores the distance from financial distress.

Piotroski F-Score

8 / 9

very strong · 8 of 9 tests passed

Altman Z''-Score

8.32

safe zone · safe above 5.85

Profitable on assets

ROA 10.2%

Cash generative

CFO PKR 20,957m

Returns improving

ROA 10.2% vs 6.2% a year ago

Earnings backed by cash

CFO PKR 20,957m vs profit PKR 23,435m

Deleveraging

debt/assets 0.10 vs 0.12

Liquidity improving

current ratio 3.04 vs 2.87

Margin expanding

gross margin 33.4% vs 26.7%

Assets working harder

asset turnover 1.46x vs 1.44x

No shareholder dilution

207m shares vs 207m

Altman components

Working capital / assets0.344

Retained earnings / assets0.362

Operating profit / assets0.144

Equity / liabilities0.636

Sales / assets1.388

Price history

Weekly closes. Beta 0.45 against the index, annualised volatility 26%, RSI 46.

+118.2% over this window

Reported accounts

The last twelve quarters as filed, in PKR millions. The publication date is what the engine uses to decide when a figure became knowable.

Quarter	Revenue	Gross profit	Operating	Net income	EPS	Filed
2025 Q4	Rs 92.2bn	Rs 36.4bn	Rs 11.8bn	Rs 8.1bn	39.05	2026-04-30
2025 Q3	Rs 90.1bn	Rs 33.7bn	Rs 10.8bn	Rs 7.3bn	35.45	2025-11-14
2025 Q2	Rs 89.7bn	Rs 31.3bn	Rs 9.8bn	Rs 6.7bn	32.40	2025-08-14
2025 Q1	Rs 82.4bn	Rs 27.7bn	Rs 8.6bn	Rs 5.8bn	27.90	2025-05-15
2024 Q4	Rs 74.9bn	Rs 19.9bn	Rs 5.7bn	Rs 3.6bn	17.35	2025-04-30
2024 Q3	Rs 76.4bn	Rs 20.6bn	Rs 5.9bn	Rs 3.6bn	17.17	2024-11-14
2024 Q2	Rs 80.3bn	Rs 22.1bn	Rs 6.4bn	Rs 3.7bn	17.69	2024-08-14
2024 Q1	Rs 76.2bn	Rs 18.1bn	Rs 4.9bn	Rs 2.6bn	12.49	2024-05-15
2023 Q4	Rs 70.4bn	Rs 20.3bn	Rs 6.0bn	Rs 3.2bn	15.55	2024-04-29
2023 Q3	Rs 73.7bn	Rs 18.3bn	Rs 5.1bn	Rs 2.5bn	11.96	2023-11-14
2023 Q2	Rs 80.4bn	Rs 14.3bn	Rs 3.2bn	Rs 1.3bn	6.32	2023-08-14
2023 Q1	Rs 74.8bn	Rs 18.3bn	Rs 5.0bn	Rs 2.8bn	13.48	2023-05-15

Ranked against Pharmaceuticals

Every peer in the same sector, ordered by composite score. These are the companies whose ratios set this one's z-scores.

FEROZFerozsons Laboratories2.1x61

ABOTAbbott Laboratories Pakistan0.4x55

AGPAGP Limited0.4x50

HINOONHighnoon Laboratories0.5x50

GLAXOGlaxoSmithKline Pakistan0.5x48

SEARLThe Searle Company0.5x46

Scored as of 31 December 2025. Generated by an automated screen for research and educational use. Not investment advice, and not a substitute for a SECP-licensed adviser.